| Targeting HIF-2α in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade | Cellular and molecular life sciences |  | | 2025 | 189 | 122 |
|
| PTPRZ1-targeting RNA CAR T cells exert antigen-specific and bystander antitumor activity in glioblastoma | Cancer immunology research | | | 2024 | 305 | 337 |
|
| Radio-chemotherapy of glioblastoma cells promotes phagocytosis by macrophages in vitro | Radiotherapy and oncology | | | 2024 | 117 | 34 |
|
| Combining antimiR-25 and cGAMP Nanocomplexes Enhances Immune Responses via M2 Macrophage Reprogramming | International journal of molecular sciences | | | 2024 | 107 | 207 |
|
| Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages | Cell communication and signaling | | | 2024 | 140 | 70 |
|
| Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy | Clinical and Experimental Medicine | | | 2024 | 106 | 49 |
|
| How to outsmart the cold tumor microenvironment: Design of STING ligand nanoparticles for improved cancer immunotherapy | OpenNano | | | 2023 | 82 | 36 |
|
| Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma | Cell death and disease | | | 2023 | 328 | 232 |
|
| Untangling macrophage/microglia complexity in glioblastoma subtypes to elucidate the impact of CSF1R inhibition | Neuro-oncology | | | 2022 | 292 | 167 |
|
| Synthesis, Formulation and Characterization of Immunotherapeutic Glycosylated Dendrimer/cGAMP Complexes for CD206 Targeted Delivery to M2 Macrophages in Cold Tumors | Pharmaceutics | | | 2022 | 257 | 112 |
|
| An update on actively targeted liposomes in advanced drug delivery to glioma | International journal of pharmaceutics |  | | 2021 | 195 | 1 |
|
| Glioma-Derived Extracellular Vesicles - Far More Than Local Mediators | Frontiers in immunology | | | 2021 | 218 | 463 |
|
| Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma | Journal for immunotherapy of cancer | | | 2021 | 281 | 340 |
|
| Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin) | JCI insight | | | 2021 | 266 | 346 |
|
| Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells | Communications Biology | | | 2021 | 349 | 232 |
|
| An experimentally defined hypoxia gene signature in glioblastoma and its modulation by metformin | Biology (Basel)[2079-7737] | | | 2020 | 489 | 337 |
|
| Cell surface GRP78: An emerging imaging marker and therapeutic target for cancer | Journal of Controlled Release | | | 2020 | 292 | 335 |
|
| Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review | Journal for immunotherapy of cancer | | | 2020 | 206 | 410 |
|
| Harnessing Microglia and Macrophages for the Treatment of Glioblastoma | Frontiers in Pharmacology | | | 2019 | 469 | 377 |
|
| Targeting self- and neoepitopes with a modular self-adjuvanting cancer vaccine | JCI Insight | | | 2019 | 312 | 3 |
|
| Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients | Neuro-Oncology | | | 2019 | 857 | 843 |
|
| Peptides as cancer vaccines | Current Opinion in Pharmacology | | | 2019 | 428 | 4 |
|
| Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models | OncoImmunology | | | 2018 | 437 | 1 |
|
| Let there be oxygen and T cells | Journal of Clinical Investigation | | | 2018 | 398 | 201 |
|
| Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines | Cellular and Molecular Life Sciences | | | 2018 | 402 | 209 |
|
| Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma | OncoImmunology | | | 2018 | 671 | 432 |
|
| Immunothérapie des gliomes : illusion ou espoir ? | Bulletin du cancer | | | 2017 | 431 | 0 |
|
| Identification of a novel population of highly cytotoxic c-Met-expressing CD8(+) T lymphocytes | EMBO Reports | | | 2017 | 602 | 4 |
|
| ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells | EMBO Journal | | | 2017 | 627 | 10 |
|
| Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? | Frontiers in Oncology | | | 2016 | 540 | 478 |
|
| Cell-penetrating peptides-the Swiss Army knife of cancer vaccines | Oncoimmunology | | | 2016 | 656 | 375 |
|
| Glioma Stemlike Cells Enhance the Killing of Glioma Differentiated Cells by Cytotoxic Lymphocytes | PloS one | | | 2016 | 583 | 309 |
|
| Hypoxia and antitumor CD8(+) T cells: An incompatible alliance? | OncoImmunology | | | 2016 | 496 | 411 |
|
| Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing | PloS one | | | 2016 | 673 | 708 |
|
| Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants | Molecular therapy | | | 2016 | 686 | 406 |
|
| Phenotypic switch of CD8(+) T cells reactivated under hypoxia toward IL-10 secreting, poorly proliferative effector cells | European Journal of Immunology | | | 2015 | 557 | 7 |
|
| Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity | Cancer research | | | 2015 | 648 | 10 |
|
| Immunotherapy of Brain Tumors | Progress in tumor research | | | 2015 | 591 | 0 |
|
| The CD40/CD40L axis in glioma progression and therapy | Neuro-oncology | | | 2015 | 504 | 248 |
|
| Immunotherapy for glioma: from illusion to realistic prospects? | American Society of Clinical Oncology educational book | | | 2014 | 1,282 | 672 |
|
| Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours | PloS one | | | 2013 | 743 | 341 |
|
| The neurotrophic hepatocyte growth factor attenuates CD8+ cytotoxic T-lymphocyte activity | Journal of neuroinflammation | | | 2013 | 634 | 406 |
|
| Getting by with a little help from the right CD4+ T cells | Oncoimmunology | | | 2013 | 592 | 286 |
|
| Maximizing output from current glioma vaccine trials to construct robust next-generation immunotherapies | Immunotherapy |  | | 2013 | 551 | 0 |
|
| Macrophages and Microglia in Brain Malignancies | Tumor Microenvironment and Myelomonocytic Cells | | | 2012 | 541 | 724 |
|
| Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy | Brain | | | 2012 | 717 | 1,701 |
|
| Oncology ESAB 2011 | | | | 2011 | 689 | 10 |
|
| Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development | Cancer research | | | 2010 | 627 | 3 |
|
| T-cell immunotherapy for malignant glioma: toward a combined approach | Current opinion in oncology | | | 2010 | 670 | 2 |
|
| Peripheral tolerance limits CNS accumulation of CD8 T cells specific for an antigen shared by tumor cells and normal astrocytes | GLIA | | | 2008 | 667 | 11 |
|
